May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Effect of Glitazone Therapy for Diabetes on Macular Thickness and Vision: Preliminary Safety Study
Author Affiliations & Notes
  • D.–U.G. Bartsch
    Univ of California–San Diego, La Jolla, CA
    Ophthalmology–Shiley Eye Ctr,
  • I. Kozak
    Univ of California–San Diego, La Jolla, CA
    Ophthalmology–Shiley Eye Ctr,
  • I. Falkenstein
    Univ of California–San Diego, La Jolla, CA
    Ophthalmology–Shiley Eye Ctr,
  • A. Tammewar
    Univ of California–San Diego, La Jolla, CA
    Ophthalmology–Shiley Eye Ctr,
  • R.R. Henry
    Univ of California–San Diego, La Jolla, CA
    Medicine,
  • P. Burke
    Univ of California–San Diego, La Jolla, CA
    Medicine,
  • L. Cheng
    Univ of California–San Diego, La Jolla, CA
    Ophthalmology–Shiley Eye Ctr,
  • W.R. Freeman
    Univ of California–San Diego, La Jolla, CA
    Ophthalmology–Shiley Eye Ctr,
  • Footnotes
    Commercial Relationships  D.G. Bartsch, None; I. Kozak, None; I. Falkenstein, None; A. Tammewar, None; R.R. Henry, None; P. Burke, None; L. Cheng, None; W.R. Freeman, None.
  • Footnotes
    Support  EY07366 (Freeman WR)
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5437. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D.–U.G. Bartsch, I. Kozak, I. Falkenstein, A. Tammewar, R.R. Henry, P. Burke, L. Cheng, W.R. Freeman; Effect of Glitazone Therapy for Diabetes on Macular Thickness and Vision: Preliminary Safety Study . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5437.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety of glitazone treatment for diabetes. Recent reports in the literature suggest that oral glitazone treatment for diabetes may cause or exacerbate retinal edema (Colucciello M. Arch Ophthalmol 123, 1273–5, 2005). Our hypothesis was that glitazone treatment may have caused subclinical edema evidenced by an increase in retinal thickness and the reports of massive macular edema represented one end of this spectrum.

Methods: : We conducted a prospective safety study of 30 subjects undergoing placebo–controlled masked treatment with pioglitazone for diabetes. To date, we have enrolled 23 subjects and 8 subjects have successfully completed both the baseline visit and 3 month visit. Patient treatment consisted of either insulin with placebo or insulin with pioglitazone. Dosing was 30 mg QD for 2 weeks and followed by a dose of 45 mg QD for 10 weeks. Vision was recorded by ETDRS chart at 4 m and retinal volume was assessed with optical coherence tomography (Stratus OCT) using the fast macular map and macular map protocol.

Results: : Two eyes were excluded due to poor scanfit at baseline. Of the remaining 14 eyes 7 showed a mild increase in macular volume 7 showed a mild decrease in macular volume as assessed by OCT fast macular map protocol. No eyes showed an increase of macular volume over 10%. Visual acuity change and macular volume change were correlated in 5 eyes and not correlated in 5 eyes. 4 eyes showed no change in either visual acuity or macular volume.

Conclusions: : Adverse ocular reactions reported with glitazone treatment such as exacerbation in diabetic macular edema are rare and idiosyncratic events. A larger study would be indicated to determine the prevalence of glitazone induced diabetic macular edema but it is an uncommon event.

Keywords: diabetic retinopathy • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×